Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

The conversation discusses hair loss treatments, specifically Breezula, Minoxidil, finasteride, and RU58841. Participants express curiosity about Breezula's safety and its steroidal nature.

KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.

The conversation is about hair regrowth progress using hormone replacement therapy (HRT) with Estradiol and Cyproterone, without using Minoxidil. The user shares progress pictures over 0, 3, and 6 months.

The user is pleased with their hair transplant results after nearly 7 months, noting thicker, longer, and stronger hair with good coverage and full donor recovery. They are using oral minoxidil and finasteride.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

RU58841 was used by some for hair loss, but concerns about side effects like gynecomastia and safety were raised. Alternatives like finasteride, minoxidil, pyrilutamide, and alfatradiol were discussed, with some users reporting better experiences with these treatments.

The conversation discusses using propanediol as an alternative to glycerin in PG-free minoxidil for better absorption. The user also plans to try nanoxidil, which may absorb more easily due to its smaller molecule size.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

The conversation is about hair regrowth progress using topical finasteride and minoxidil twice daily, with occasional microneedling. The user also uses Minoxidilmax and WOW Skin Science Apple Cider Vinegar Shampoo.

Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

The conversation is about sourcing Winlevi (clascoterone) for personal use in the EU. The user is specifically looking for a non-generic version.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

The user has been on finasteride for 7 years and had a hair transplant, but is experiencing hair thinning and itchiness, particularly on one side, leading to concerns about male pattern baldness or other health issues. Despite having a full head of hair, the user is considering shaving it due to mental health struggles and is advised to consult a therapist and consider other treatments like minoxidil or dutasteride.

A 37-year-old male started a hair loss treatment 7 weeks ago using 1mg finasteride, 1.5mg minoxidil, and microneedling, with noticeable coverage improvement except for the right temple. He is considering a hair transplant in the future if needed.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

The conversation discusses a hair loss treatment regimen including oral dutasteride, oral minoxidil, tadalafil, and the recent addition of RU58841. The user shares experiences with these treatments, noting significant hair regrowth and stabilization, and discusses the cost and preparation of RU58841.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

The user is considering switching from topical finasteride to RU58841 or KX826 due to side effects like low libido and ED. They are also using oral minoxidil and considering low-dose saw palmetto to maintain their hairline.

The user reported positive results using KX-826 0.5% twice daily for hair loss, noting progress in the temple area with no systemic side effects. They avoided finasteride and minoxidil due to concerns about side effects and inconvenience, respectively, and used ketoconazole shampoo for seborrheic dermatitis.

A 31-year-old has been using 1mg finasteride, 5mg minoxidil, minoxidil spray, a dermaroller, and Nizoral shampoo for hair regrowth. The treatments have resulted in thick, healthy hair, and the user has been on finasteride since 2022, switching from lotion to pills in 2025.

The user shared progress after 7 months of hair loss treatment using topical minoxidil with finasteride, oral minoxidil, microneedling, LLLT laser cap, and scalp massage. They reported thicker, denser hair with no significant side effects.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

The conversation is about dealing with hair loss and exploring treatments like HRT, Minoxidil, and micro-needling. The user is considering wigs and possibly a hair transplant while expressing feelings of self-doubt and seeking support.

The user is experiencing positive results in hair regrowth after 7 months of using oral minoxidil (2.5mg) and dutasteride (0.5mg). They noticed reduced hair loss by the second month and hair growth and thickening by the fifth month, with no side effects reported.